Nanaimo Research Institute
CURRENT STUDIES
|
Nanaimo Research Institute |
|||||
|
|
CURRENT STUDIES |
||||
|
|
NANAIMO RESEARCH INSTITUTE (NRI) Studies Past studies at NRI include numerous cardiac (acute coronary syndrome, congestive heart failure, atrial fibrillation), orthopaedic, diabetic and palliative care studies. Following is a list of our current studies: ARISTOTLE STUDY -- a phase 3, active (warfarin) controlled, randomized, double-blind, parallel arm study to evaluate efficacy and safety of apixaban in preventing stroke and systemic embolism in subjects with nonvalvular atrial fibrillation. dal-OUTCOMES a phase III, double-blind, randomized, placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients with a documented recent Acute Coronary Syndrome (ACS) characterised by biomarker or ECG changes and consistent with international definitions. Dalcetrapib has been shown to reduce CETP (cholesteryl ester transfer protein)activity therby increasing HDL-C levels. This is the first clinical trial to evaluate the effect of increasing HDL-C through effects on CETP on cardiovascular outcomes in patients with a recent acute coronary syndrome.¨ RELY-ABLE STUDY long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomized trial to assess the effect of a knowledge translation intervention on patient outcomes TRA2°P – TIMI 50 a Phase 3, double-blind, randomized, placebo-controlled multinational study evaluating a novel thrombin receptor antagonist (SCH 530348) as secondary prevention of atherothrombotic ischemic events in the setting of stable CAD, CVD and PAD. SCH 530348 has a unique mechanism of inhibiting platelets by interfering with thrombin-receptor mediated activation that appears to have potent anti-platelet effects with a potential for less bleeding that with thienopyridines. Subjects on this study will receive SCH 530348 or placebo above standard of care treatment. Updated 30 Apr 2009 |
